Edwards Lifesciences Stock Forecast, Price & News

19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 2 sell ratings, 5 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Edwards Lifesciences stock.
View analyst ratings for Edwards Lifesciences or view top-rated stocks.

Wall Street analysts have given Edwards Lifesciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Edwards Lifesciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Edwards Lifesciences is scheduled to release its next quarterly earnings announcement on Thursday, April 22nd 2021.
View our earnings forecast for Edwards Lifesciences.

Edwards Lifesciences Co. (NYSE:EW) released its earnings results on Tuesday, January, 26th. The medical research company reported $0.50 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.53 by $0.03. The medical research company had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.18 billion. Edwards Lifesciences had a net margin of 18.18% and a trailing twelve-month return on equity of 29.00%. The company's revenue was up 1.5% compared to the same quarter last year. During the same period last year, the business earned $1.46 EPS.
View Edwards Lifesciences' earnings history.

Edwards Lifesciences' stock was trading at $65.79 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EW stock has increased by 27.6% and is now trading at $83.97.
View which stocks have been most impacted by COVID-19.

Shares of Edwards Lifesciences split on the morning of Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly minted shares were issued to shareholders after the market closes on Monday, May 18th 2020. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 300 shares after the split.

Edwards Lifesciences issued an update on its FY21 earnings guidance on Wednesday, January, 27th. The company provided EPS guidance of $2.00-2.20 for the period, compared to the Thomson Reuters consensus estimate of $2.13. The company issued revenue guidance of $4.90-5.30 billion, compared to the consensus revenue estimate of $5.10 billion.

19 analysts have issued 1-year target prices for Edwards Lifesciences' shares. Their forecasts range from $51.67 to $111.00. On average, they expect Edwards Lifesciences' stock price to reach $91.54 in the next twelve months. This suggests a possible upside of 9.0% from the stock's current price.
View analysts' price targets for Edwards Lifesciences or view top-rated stocks among Wall Street analysts.

389 employees have rated Edwards Lifesciences CEO Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among Edwards Lifesciences' employees.

Some companies that are related to Edwards Lifesciences include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Boston Scientific (BSX), IDEXX Laboratories (IDXX), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Insulet (PODD), Varian Medical Systems (VAR) and STERIS (STE).
View all of EW's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), The Home Depot (HD), salesforce.com (CRM), The Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Edwards Lifesciences' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (9.40%), Bank of New York Mellon Corp (3.50%), Brown Advisory Inc. (2.18%), Alliancebernstein L.P. (2.06%), Sands Capital Management LLC (1.86%) and Janus Henderson Group PLC (1.56%). Company insiders that own Edwards Lifesciences stock include Catherine M Szyman, Donald E Bobo Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link.
View institutional ownership trends for Edwards Lifesciences.

EW stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Alliancebernstein L.P., Jennison Associates LLC, Sands Capital Management LLC, BlackRock Inc., Northern Trust Corp, Charles Schwab Investment Management Inc., and Schroder Investment Management Group. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers, and Scott B Ullem.
View insider buying and selling activity for Edwards Lifesciences or view top insider-selling stocks.

EW stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Bank of New York Mellon Corp, Brown Advisory Inc., Ownership Capital B.V., Jackson Square Partners LLC, Royal London Asset Management Ltd., Ardevora Asset Management LLP, and Fisher Asset Management LLC.
View insider buying and selling activity for Edwards Lifesciences or or view top insider-buying stocks.

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EW stock can currently be purchased for approximately $83.97.

Edwards Lifesciences has a market capitalization of $52.44 billion and generates $4.35 billion in revenue each year. The medical research company earns $1.05 billion in net income (profit) each year or $1.86 on an earnings per share basis.

Edwards Lifesciences employs 13,900 workers across the globe.

The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.

Edwards Lifesciences was founded in 1958.

The official website for Edwards Lifesciences is www.edwards.com.

Edwards Lifesciences is headquartered at ONE EDWARDS WAY, IRVINE CA, 92614.

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at 949-250-2500 or via email at [email protected]